BiotechTube
Home/Pipeline/Pipeline Candidate (e.g., RNTX-201)

Pipeline Candidate (e.g., RNTX-201)

Parkinson's Disease

Preclinical / Phase 1Active (Inferred)Not Publicly Disclosed

Key Facts

Indication
Parkinson's Disease
Phase
Preclinical / Phase 1
Status
Active (Inferred)
Company
Rein Therapeutics

About Rein Therapeutics

Rein Therapeutics is a US-based, public biotech company (RNTX) with a mission to develop disease-modifying therapies for neurological disorders. The company is advancing a pipeline of novel candidates through clinical development, targeting core pathways in neurodegeneration. Its strategy hinges on translating its proprietary platform into differentiated therapeutics for high-value indications, positioning it as a specialized player in the challenging neurology space.

View full company profile

Therapeutic Areas

NeurologyNeurodegenerative Diseases

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical
golexanoloneUmecrine CognitionPreclinical
Bezisterim (NE3107)BioViePhase 2
Cannabinoid-based TherapyGb SciencesPreclinical